TNP-2198

DRUG5 trials

Sponsors

TenNor Therapeutics (Suzhou) Limited, TenNor Therapeutics Inc.

Conditions

Helicobacter Pylori Infection

Phase 1

A Study to Evaluate Preliminary Helicobacter Pylori Eradication After Multiple Doses of TNP-2198 Capsules Combined With Rabeprazole Sodium Enteric-coated Tablets, or Rabeprazole Sodium Enteric-coated Tablets and Amoxicillin Capsules

CompletedNCT06076681

TenNor Therapeutics (Suzhou) LimitedHelicobacter Pylori Infection

Start: 2021-09-27End: 2022-01-06Updated: 2023-11-22

A Study to Evaluate the Safety, Tolerability, Pharmacokinetics and Food Effect of TNP-2198 Capsules After Single Oral Dose in Healthy Participants

CompletedNCT06081699

TenNor Therapeutics (Suzhou) LimitedHelicobacter Pylori Infection

Start: 2019-05-09End: 2019-09-18Updated: 2023-10-13

A Study to Investigate the Safety, Tolerability, and Pharmacokinetics of TNP-2198 Capsules in Asymptomatic Participants With Helicobacter Pylori Infection

CompletedNCT06081712

TenNor Therapeutics (Suzhou) LimitedHelicobacter Pylori Infection

Start: 2020-10-20End: 2021-07-15Updated: 2023-10-13

Drug-Drug Interactions Between TNP-2198 and Midazolam, Clarithromycin

CompletedNCT06551623

TenNor Therapeutics Inc.Helicobacter Pylori Infection

Start: 2024-08-26End: 2024-10-14Updated: 2024-10-24

Phase 2

Efficacy and Safety After Multiple Doses of TNP-2198 Capsules, Rabeprazole Sodium Enteric-coated Tablets and Amoxicillin Capsules in Helicobacter Pylori Infected-positive Participants

CompletedNCT06076694

TenNor Therapeutics (Suzhou) LimitedHelicobacter Pylori Infection

Start: 2022-06-26End: 2022-09-20Updated: 2023-12-12

Related Papers

Safety, pharmacokinetics, and efficacy of rifasutenizol, a novel dual-targeted antibacterial agent in healthy participants and patients in China with Helicobacter pylori infection: four randomised clinical trials.

2024-02-1210 citations